Aclaris Therapeutics, Inc. (ACRS)
NASDAQ: ACRS · Real-Time Price · USD
4.320
-0.090 (-2.04%)
Apr 28, 2026, 11:39 AM EDT - Market open
Aclaris Therapeutics Revenue
In the year 2025, Aclaris Therapeutics had annual revenue of $7.83M, down -58.19%. Aclaris Therapeutics had revenue of $1.30M in the quarter ending December 31, 2025, a decrease of -85.94%.
Revenue (ttm)
$7.83M
Revenue Growth
-58.20%
P/S Ratio
78.32
Revenue / Employee
$107,205
Employees
73
Market Cap
600.46M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 7.83M | -10.89M | -58.19% |
| Dec 31, 2024 | 18.72M | -12.53M | -40.09% |
| Dec 31, 2023 | 31.25M | 1.50M | 5.03% |
| Dec 31, 2022 | 29.75M | 22.99M | 340.05% |
| Dec 31, 2021 | 6.76M | 279.00K | 4.30% |
| Dec 31, 2020 | 6.48M | 2.26M | 53.35% |
| Dec 31, 2019 | 4.23M | -1.92M | -31.28% |
| Dec 31, 2018 | 6.15M | 4.47M | 265.48% |
| Dec 31, 2017 | 1.68M | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| CorMedix | 311.71M |
| Rigel Pharmaceuticals | 294.28M |
| Zevra Therapeutics | 106.47M |
| Prothena Corporation | 9.68M |
| Adlai Nortye | 5.00M |
| Ocugen | 4.41M |
| Absci | 2.80M |
| Shattuck Labs | 1.00M |
ACRS News
- 5 hours ago - Aclaris Therapeutics Announces Positive Full Top Line First-in-Human Results from Phase 1a Healthy Volunteer Clinical Trial of ATI-052, a Novel Potential First-in-Class Anti-TSLP/IL-4Rα Bispecific Antibody, and Announces Lichen Planus as Lead Indication for ATI-2138, an Oral ITK/JAK3 Inhibitor - GlobeNewsWire
- 18 hours ago - Aclaris Therapeutics to Provide Clinical Update on Key Biologic and Oral Inhibitor Programs on April 28, 2026 - GlobeNewsWire
- 13 days ago - Aclaris Therapeutics Transcript: H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference - Transcripts
- 20 days ago - Aclaris Therapeutics to Participate in the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference - GlobeNewsWire
- 4 weeks ago - Results Presented at 2026 American Academy of Dermatology (AAD) Annual Meeting Provide Additional Support for the Therapeutic Potential of ATI-2138 - GlobeNewsWire
- 5 weeks ago - Aclaris Therapeutics Announces Poster on Results from Phase 2a Trial of ATI-2138 at the 2026 American Academy of Dermatology (AAD) Annual Meeting - GlobeNewsWire
- 5 weeks ago - Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis - GlobeNewsWire
- 6 weeks ago - Aclaris Therapeutics Transcript: Leerink Global Healthcare Conference 2026 - Transcripts